FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Norihiro Nishimoto

Research Profile

Chemicals & Drugs

Disorders

Physiology

Living Beings

Mouse

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Procedures

Reverse Transcriptase Polymerase Chain Reaction

Co-author Network

Publications

TOP 3
Makoto Hirao; Yoshitaka Kawato; Akihide Nampei; Norihiro Nishimoto; Hiroki Oze; Kenrin Shi; Naomi Yamasaki; Hideki Yoshikawa; Kosuke Ebina; Jun Hashimoto
Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab.
Masahiro Terada; Fuminori Kawano; Naoya Nakai; Norihiro Nishimoto; Takashi Ohira; Yoshinobu Ohira
Effects of mechanical over-loading on the properties of soleus muscle fibers, with or without damage, in wild type and mdx mice.
Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Hideki Yoshikawa; Norihiro Nishimoto
Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Norihiro Nishimoto (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Makoto Hirao; Yoshitaka Kawato; Akihide Nampei; Norihiro Nishimoto; Hiroki Oze; Kenrin Shi; Naomi Yamasaki; Hideki Yoshikawa; Kosuke Ebina; Jun Hashimoto
Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab.
Rheumatology international 2012;32(12):4041-5.
2012: Masahiro Terada; Fuminori Kawano; Naoya Nakai; Norihiro Nishimoto; Takashi Ohira; Yoshinobu Ohira
Effects of mechanical over-loading on the properties of soleus muscle fibers, with or without damage, in wild type and mdx mice.
PloS one 2012;7(4):e34557.
2011: Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Hideki Yoshikawa; Norihiro Nishimoto
Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.
Modern rheumatology / the Japan Rheumatism Association 2011;21(1):10-5.
2011: Hooi-Ming Lee; Chieko Aoki; Kensuke Ochi; Takahiro Ochi; Yasunori Shimaoka; Hidehiko Sugino; Ryuji Suzuki; Norihiro Nishimoto
Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis.
Arthritis research & therapy 2011;13(3):R89.
2011: Hooi-Ming Lee; Chieko Aoki; Hidehiko Sugino; Norihiro Nishimoto
Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus.
Arthritis research & therapy 2011;13(2):R63.
2010: Toshiyuki Ogata; Hideya Yamazaki; Teruki Teshima; Ayaka Kihara; Yuko Suzumoto; Takehiro Inoue; Norihiro Nishimoto; Nariaki Matsuura
Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.
Radiation oncology (London, England) 2010;5():26.
2010: Masahiro Terada; Yong Bo Lan; Fuminori Kawano; Takashi Ohira; Yoko Higo; Naoya Nakai; Kazuhiko Imaizumi; Akihiko Ogura; Norihiro Nishimoto; Yasuo Adachi; Yoshinobu Ohira
Myonucleus-related properties in soleus muscle fibers of mdx mice.
Cells, tissues, organs 2010;191(3):248-59.
2009: Yasuhiro Take; Ken Nakata; Jun Hashimoto; Hideki Tsuboi; Norihiro Nishimoto; Takahiro Ochi; Hideki Yoshikawa
Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6.
Arthritis and rheumatism 2009;60(12):3591-601.
2009: Norihiro Nishimoto; N Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
Annals of the rheumatic diseases 2009;68(10):1580-4.
2009: Makoto Hirao; Jun Hashimoto; Hideki Tsuboi; Akihide Nampei; Hideko Nakahara; N Yoshio; Toru Mima; Hideki Yoshikawa; Norihiro Nishimoto
Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab.
Annals of the rheumatic diseases 2009;68(5):654-7.
2009: S Ishikawa; T Mima; C Aoki; N Yoshio-Hoshino; Y Adachi; T Imagawa; Masaki Mori; M Tomiita; N Iwata; T Murata; M Miyoshi; S Takei; Y Aihara; S Yokota; K Matsubara; Norihiro Nishimoto
Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis.
Annals of the rheumatic diseases 2009;68(2):264-72.
2009: Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Hideki Yoshikawa; Norihiro Nishimoto
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
Modern rheumatology / the Japan Rheumatism Association 2009;19(3):273-82.
2009: Hooi-Ming Lee; Toru Mima; Hidehiko Sugino; Chieko Aoki; Yasuo Adachi; Naoko Yoshio-Hoshino; Kenichi Matsubara; Norihiro Nishimoto
Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus.
Arthritis research & therapy 2009;11(1):R1.
2009: Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Modern rheumatology / the Japan Rheumatism Association 2009;19(1):12-9.
2009: Hideko Nakahara; Toru Mima; Naoko Yoshio-Hoshino; Masato Matsushita; Jun Hashimoto; Norihiro Nishimoto
A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.
Modern rheumatology / the Japan Rheumatism Association 2009;19(1):69-72.
2008: Norihiro Nishimoto; Kimio Terao; Toru Mima; Hideko Nakahara; Nobuhiro Takagi; Takahiro Kakehi
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Blood 2008;112(10):3959-64.
2008: Yasuo Adachi; Naoko Yoshio-Hoshino; Norihiro Nishimoto
Gene therapy for multiple myeloma.
Current gene therapy 2008;8(4):247-55.
2008: Norihiro Nishimoto; Hideko Nakahara; Naoko Yoshio-Hoshino; Toru Mima
Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.
Arthritis and rheumatism 2008;58(4):1197-200.
2008: Toru Mima; Norihiro Nishimoto
Tocilizumab for the treatment of rheumatoid arthritis.
Expert review of clinical immunology 2008;4(2):165-72.
2008: Yasuo Adachi; Naoko Yoshio-Hoshino; Norihiro Nishimoto
The blockade of IL-6 signaling in rational drug design.
Current pharmaceutical design 2008;14(12):1217-24.
2008: Akihide Nampei; Jun Hashimoto; Junichiro Koyanagi; Takeshi Ono; Hideo Hashimoto; Noriyuki Tsumaki; Tetsuya Tomita; Kazuomi Sugamoto; Norihiro Nishimoto; Takahiro Ochi; Hideki Yoshikawa
Characteristics of fracture and related factors in patients with rheumatoid arthritis.
Modern rheumatology / the Japan Rheumatism Association 2008;18(2):170-6.
2007: Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
Annals of the rheumatic diseases 2007;66(9):1162-7.
2007: Norihiro Nishimoto
[Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nihon rinsho. Japanese journal of clinical medicine 2007;65(7):1218-25.
2007: Norihiro Nishimoto
[Clinical benefits of anti-human IL-6 receptor antibody therapy].
Clinical calcium 2007;17(4):562-8.
2007: Naoko Yoshio-Hoshino; Yasuo Adachi; Chieko Aoki; Alexander Pereboev; David T Curiel; Norihiro Nishimoto
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
Cancer research 2007;67(3):871-5.
2006: Hideko Nakahara; Norihiro Nishimoto
Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Endocrine, metabolic & immune disorders drug targets 2006;6(4):373-81.
2006: Norihiro Nishimoto; Tadamitsu Kishimoto
Interleukin 6: from bench to bedside.
Nature clinical practice. Rheumatology 2006;2(11):619-26.
2006: Norihiro Nishimoto
[Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology 2006;29(5):289-94.
2006: Yasuo Adachi; Chieko Aoki; Naoko Yoshio-Hoshino; Koichi Takayama; David T Curiel; Norihiro Nishimoto
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.
International journal of cancer. Journal international du cancer 2006;119(6):1303-11.
2006: Norihiro Nishimoto
Interleukin-6 in rheumatoid arthritis.
Current opinion in rheumatology 2006;18(3):277-81.
2005: Norihiro Nishimoto; Yuzuru Kanakura; Katsuyuki Aozasa; Takeshi Johkoh; Minoru Nakamura; Shuji Nakano; Nobuaki Nakano; Yasuo Ikeda; Takeshi Sasaki; Kiyoshi Nishioka; Masamichi Hara; Hirokuni Taguchi; Yukihiko Kimura; Yoshiro Kato; Hideki Asaoku; Shunichi Kumagai; Fumio Kodama; Hideko Nakahara; Keisuke Hagihara; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.
Blood 2005;106(8):2627-32.
2005: Norihiro Nishimoto
Cytokine signal regulation and autoimmune disorders.
Autoimmunity 2005;38(5):359-67.
2005: Norihiro Nishimoto
Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Clinical reviews in allergy & immunology 2005;28(3):221-30.
2005: Kanji Sugimoto; Norihiro Nishimoto; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Tsunehiko Nishimura
Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody.
Annals of nuclear medicine 2005;19(4):261-6.
2005: Norihiro Nishimoto
[Anti-IL-6 receptor antibody].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 5():723-7.
2005: Masahiko Mihara; Norihiro Nishimoto; Yoshiyuki Ohsugi
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
Expert opinion on biological therapy 2005;5(5):683-90.
2005: Norihiro Nishimoto; Masahiko Mihara
[MRA for therapy of rheumatoid arthritis].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 1():538-43.
2005: Masahiko Mihara; Norihiro Nishimoto
[Interleukin-6 in pathogenesis of rheumatoid arthritis].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 1():158-62.
2005: Yoshihito Shima; Masayuki Iwano; Kazuyuki Yoshizaki; Toshio Tanaka; Ichiro Kawase; Norihiro Nishimoto
All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice.
Nephron. Experimental nephrology 2005;100(1):e54-62.
2004: Norihiro Nishimoto; Tadamitsu Kishimoto
Inhibition of IL-6 for the treatment of inflammatory diseases.
Current opinion in pharmacology 2004;4(4):386-91.
2004: Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2004;50(6):1761-9.
2004: Masahiko Mihara; Masashi Shiina; Norihiro Nishimoto; Kazuyuki Yoshizaki; Tadamitsu Kishimoto; Ken-Ichi Akamatsu
Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis.
The Journal of rheumatology 2004;31(6):1132-8.
2004: Hiroaki Ito; Masakazu Takazoe; Yoshihiro Fukuda; Toshifumi Hibi; Kazuo Kusugami; Akira Andoh; Takayuki Matsumoto; Takehira Yamamura; Junichi Azuma; Norihiro Nishimoto; Kazuyuki Yoshizaki; Takashi Shimoyama; Tadamitsu Kishimoto
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
Gastroenterology 2004;126(4):989-96; discussion 947.
2003: Yukihiko Saeki; Toru Mima; Taeko Ishii; Atsushi Ogata; Hideyuki Kobayashi; Shiro Ohshima; Tetsushi Ishida; Youichiro Tabunoki; Hitoshi Kitayama; Masao Mizuki; Yoshinori Katada; Hideki Asaoku; Masayasu Kitano; Norihiro Nishimoto; Kazuyuki Yoshizaki; Masahiro Maeda; Shigeyuki Kon; Naokazu Kinoshita; Toshimitsu Uede; Ichiro Kawase
Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.
British journal of haematology 2003;123(2):263-70.
2003: Norihiro Nishimoto; Kazuyuki Yoshizaki; Keiji Maeda; Taro Kuritani; Hitoshi Deguchi; Bunzo Sato; Nobuyuki Imai; Masaki Suemura; Takahiro Kakehi; Nobuhiro Takagi; Tadamitsu Kishimoto
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
The Journal of rheumatology 2003;30(7):1426-35.
2003: Hideko Nakahara; Jian Song; Masamichi Sugimoto; Keisuke Hagihara; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Norihiro Nishimoto
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Arthritis and rheumatism 2003;48(6):1521-9.
2003: Sho Goya; Hiroto Matsuoka; Masahide Mori; Hiroshi Morishita; Hiroshi Kida; Yoichiro Kobashi; Terufumi Kato; Yoshio Taguchi; Tadashi Osaki; Isao Tachibana; Norihiro Nishimoto; Kazuyuki Yoshizaki; Ichiro Kawase; Seiji Hayashi
Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung.
The Journal of pathology 2003;200(1):82-7.
2002: Asao Katsume; Hiroyuki Saito; Yoshiki Yamada; Keigo Yorozu; Otoya Ueda; Ken-ichi Akamatsu; Norihiro Nishimoto; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Yoshiyuki Ohsugi
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice.
Cytokine 2002;20(6):304-11.
2002: Makoto Okazaki; Yoshiki Yamada; Norihiro Nishimoto; Kazuyuki Yoshizaki; Masahiko Mihara
Characterization of anti-mouse interleukin-6 receptor antibody.
Immunology letters 2002;84(3):231-40.
2002: Masahiko Mihara; Norihiro Nishimoto; Kazuyuki Yoshizaki; Takashi Suzuki
Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice.
Immunology letters 2002;84(3):223-9.
2002: Keisuke Hagihara; Norihiro Nishimoto; Kazuyuki Yoshizaki
[A humanized anti-IL-6 receptor antibody(MRA) in RA therapy].
Nihon rinsho. Japanese journal of clinical medicine 2002;60(12):2401-7.
2002: Jian Song; Takako Ohkura; Masamichi Sugimoto; Yasuko Mori; Reiko Inagi; Koichi Yamanishi; Kazuyuki Yoshizaki; Norihiro Nishimoto
Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line.
Journal of medical virology 2002;68(3):404-11.
2002: Tetsuji Naka; Norihiro Nishimoto; Tadamitsu Kishimoto
The paradigm of IL-6: from basic science to medicine.
Arthritis research 2002;4 Suppl 3():S233-42.
2001: Masahiko Mihara; M Kotoh; Norihiro Nishimoto; Y Oda; E Kumagai; N Takagi; K Tsunemi; Yoshiyuki Ohsugi; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Y Takeda
Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.
Clinical immunology (Orlando, Fla.) 2001;98(3):319-26.
2000: Norihiro Nishimoto; T Okura; Jian Song; Reiko Inagi; Yasuko Mori; Koichi Yamanishi; Kazuyuki Yoshizaki
[Crosstalking between HIV and HHV-8 via IL-6 in AIDS].
Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology 2000;23(6):586-90.
2000: Norihiro Nishimoto; Tadamitsu Kishimoto; Kazuyuki Yoshizaki
Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
Annals of the rheumatic diseases 2000;59 Suppl 1():i21-7.
2000: Yasuko Mori; Norihiro Nishimoto; M Ohno; Reiko Inagi; Panadda Dhepakson; K Amou; Kazuyuki Yoshizaki; Koichi Yamanishi
Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion.
Journal of medical virology 2000;61(3):332-5.
2000: Norihiro Nishimoto; A Ito; M Ono; H Tagoh; Takayuki Matsumoto; T Tomita; T Ochi; Kazuyuki Yoshizaki
IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor.
International immunology 2000;12(2):187-93.
2000: Norihiro Nishimoto; M Sasai; Yoshihito Shima; Masashi Nakagawa; Takayuki Matsumoto; T Shirai; Tadamitsu Kishimoto; Kazuyuki Yoshizaki
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Blood 2000;95(1):56-61.
1999: Norihiro Nishimoto; Tadamitsu Kishimoto; Kazuyuki Yoshizaki
Anticytokine therapy in autoimmune diseases.
Internal medicine (Tokyo, Japan) 1999;38(2):178-82.
1998: Takeshi Johkoh; Nestor L Müller; Kazuya Ichikado; Norihiro Nishimoto; Kazuyuki Yoshizaki; Osamu Honda; Noriyuki Tomiyama; H Naitoh; Hideji Nakamura; Shuji Yamamoto
Intrathoracic multicentric Castleman disease: CT findings in 12 patients.
Radiology 1998;209(2):477-81.
1998: Kazuyuki Yoshizaki; Norihiro Nishimoto; M Mihara; Tadamitsu Kishimoto
Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
Springer seminars in immunopathology 1998;20(1-2):247-59.
1997: Norihiro Nishimoto; Yoshihito Shima; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Myeloma biology and therapy. Present status and future developments.
Hematology/oncology clinics of North America 1997;11(1):159-72.
1997: Norihiro Nishimoto; Sachiko Suematsu; T Kishimoto
Plasma cell dyscrasias.
Advances in immunology 1997;64():219-81.
1996: JT Tang; Hideya Yamazaki; Norihiro Nishimoto; T Inoue; Takayuki Nose; Masahiko Koizumi; Eiichi Tanaka; A Ogata; Kazuyuki Yoshizaki; T Inoue
Effect of radiotherapy on serum level of interleukin 6 in patients with cervical carcinoma.
Anticancer research 1996;16(4A):2005-8.
1995: Hideya Yamazaki; Norihiro Nishimoto; H Oi; M Matsushita; A Ogata; Y Shima; T Inoue; JT Tang; Kazuyuki Yoshizaki; T Kishimoto
Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolization.
Cytokine 1995;7(2):191-5.
1995: Y Shima; Norihiro Nishimoto; A Ogata; Y Fujii; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
Blood 1995;85(3):757-64.
1995: Y Tani; Norihiro Nishimoto; A Ogata; Y Shima; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Gp130 in human myeloma/plasmacytoma.
Current topics in microbiology and immunology 1995;194():229-33.
1994: A Ogata; Norihiro Nishimoto; Y Shima; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.
Blood 1994;84(9):3040-6.
1994: Norihiro Nishimoto; A Ogata; Y Shima; Y Tani; H Ogawa; M Nakagawa; H Sugiyama; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.
The Journal of experimental medicine 1994;179(4):1343-7.
1993: Hiroki Ohzato; Morito Monden; Kazuyuki Yoshizaki; A Ogata; Norihiro Nishimoto; M Gotoh; Tadamitsu Kishimoto; T Mori
Systemic production of interleukin-6 following acute inflammation.
Biochemical and biophysical research communications 1993;197(3):1556-62.
1993: Hiroki Ohzato; Morito Monden; Kazuyuki Yoshizaki; M Gotoh; T Kanai; Koji Umeshita; T Tono; Norihiro Nishimoto; T Kishimoto; T Mori
Serum interleukin-6 levels as an indicator of acute rejection after liver transplantation in cynomologous monkeys.
Surgery today 1993;23(6):521-7.
1992: Hiroki Ohzato; Kazuyuki Yoshizaki; Norihiro Nishimoto; A Ogata; H Tagoh; Morito Monden; M Gotoh; Tadamitsu Kishimoto; T Mori
Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.
Surgery 1992;111(2):201-9.
1990: Kazuyuki Yoshizaki; Norihiro Nishimoto; K Matsumoto; H Tagoh; Tetsuya Taga; Y Deguchi; T Kuritani; Toshio Hirano; K Hashimoto; N Okada
Interleukin 6 and expression of its receptor on epidermal keratinocytes.
Cytokine 1990;2(5):381-7.
1990: Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobutaka Eiraku; K Machigashira; H Tagoh; A Ogata; T Kuritani; Mitsuhiro Osame; Tadamitsu Kishimoto
Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis.
Journal of the neurological sciences 1990;97(2-3):183-93.
1989: Kazuyuki Yoshizaki; Toshio Matsuda; Norihiro Nishimoto; T Kuritani; L Taeho; Katsuyuki Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
Blood 1989;74(4):1360-7.
1989: Norihiro Nishimoto; Kazuyuki Yoshizaki; H Tagoh; Morito Monden; S Kishimoto; Toshio Hirano; Tadamitsu Kishimoto
Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation.
Clinical immunology and immunopathology 1989;50(3):399-401.